GlassScriptPhysician profile
Salman Q Sheikh
NPI 1396753083
$1,668.17
in general payments reported to CMS, 2019-2025
21 companies · $83.94 in 2025
The $83.94 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $96.65 · 2022: $59.65 · 2023: $674 · 2024: $559 · 2025: $83.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,299 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.09 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $563.27 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.03 | 2019-2024 | Ofev, Spiriva Respimat, Combivent Respimat |
| Galvanize Therapeutics, INC | $135.58 | 2023 | Aliya System |
| Mylan Specialty L.P. | $125.03 | 2020-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $76.99 | 2020-2024 | Airsupra, Breztri |
| Electromed, INC. | $71.16 | 2023-2024 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $68.47 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $68.21 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $62.22 | 2019 | |
| Amgen INC. | $46.29 | 2023-2024 | Tezspire |
| Insmed, INC. | $37.39 | 2025 | Brinsupri, Arikayce |
| Pulmonx Corporation | $30.31 | 2022-2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Inogen, INC. | $29.39 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Merck Sharp & Dohme LLC | $18.62 | 2023 | |
| Sunovion Pharmaceuticals INC. | $17.89 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $16.50 | 2020 | |
| Verona Pharma, INC. | $16.47 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $16.15 | 2019 | |
| Advanced Respiratory, INC | $16.12 | 2019 | |
| Ambu INC. | $14.86 | 2025 | |
| Resmed Corp | $11.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salman Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.